Keywords: Takeda,, Edarbi, Hypertension, GlaxoSmithKline, Promacta, ITO, Idiopathic thrombocytoopenic purpura, USA, FDA

US FDA clears Takeda’s Edarbi for hypertension and grants full approval for GSK’s Promacta

Article | 28 February 2011

Print This

The US Food and Drug Administration on Friday approved Edarbi (azilsartan medoxomil), from Japan’s largest drugmaker Takeda (TSE: 4502), ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in